2,440 Shares in IDEXX Laboratories, Inc. (NASDAQ:IDXX) Bought by Allstate Corp

Allstate Corp acquired a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,440 shares of the company’s stock, valued at approximately $1,009,000.

Other large investors also recently bought and sold shares of the company. Insight Wealth Strategies LLC boosted its stake in shares of IDEXX Laboratories by 230.5% in the fourth quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock valued at $4,174,000 after buying an additional 7,041 shares in the last quarter. Geode Capital Management LLC lifted its holdings in IDEXX Laboratories by 1.8% in the third quarter. Geode Capital Management LLC now owns 2,259,537 shares of the company’s stock valued at $1,138,732,000 after acquiring an additional 40,349 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter worth $1,263,000. Sax Wealth Advisors LLC grew its stake in shares of IDEXX Laboratories by 76.3% during the 4th quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company’s stock worth $590,000 after purchasing an additional 617 shares during the period. Finally, Hantz Financial Services Inc. increased its holdings in shares of IDEXX Laboratories by 11.5% in the 4th quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company’s stock valued at $3,199,000 after purchasing an additional 800 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling

In other news, Director M Anne Szostak sold 3,000 shares of the firm’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the sale, the director now owns 3,061 shares in the company, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages have weighed in on IDXX. Morgan Stanley lowered their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Tuesday, March 25th. Piper Sandler boosted their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Bank of America raised their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research report on Tuesday, February 4th. Finally, Barclays boosted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $415.87 on Monday. The firm has a market cap of $33.71 billion, a price-to-earnings ratio of 38.98, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The company’s 50-day moving average is $437.07 and its two-hundred day moving average is $442.57.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.